A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.

NCT02635945 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: PBF-680
DRUG: Placebo

Sponsor

Palobiofarma SL

Collaborators

[object Object]
[object Object]